Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS

(2021) Chenxin Chen et al.   Frontiers in Pharmacology

Treatment and Disease‐related Complications in Multiple Myeloma: Implications for Survivorship

(2020) Rajshekhar Chakraborty et al.   AMERICAN JOURNAL OF HEMATOLOGY

Association Between Antipsychotics and Osteoporosis Based on Real-World Data

(2020) Satoshi Yokoyama et al.   ANNALS OF PHARMACOTHERAPY

Hematological toxicities in immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019

(2020) Xiaofei Ye et al.   HEMATOLOGICAL ONCOLOGY

Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System

(2020) Jing Huang et al.   Scientific Reports

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)

(2020) Santa Cirmi et al.   Cancers

Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review

(2020) Larysa Sanchez et al.   Expert Review of Hematology

Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management

(2020) Perry Wu et al.   Current Oncology Reports

Management of cardiovascular risk in patients with multiple myeloma

(2019) Chris Plummer et al.   Blood Cancer Journal

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension

(2019) Sara Bringhen et al.   JOURNAL OF INTERNAL MEDICINE

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

(2019) Douglas B. Johnson et al.   Journal for ImmunoTherapy of Cancer

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study

(2019) Shinsuke Iida et al.   CANCER SCIENCE

Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER‐Medicare database

(2019) Bita Fakhri et al.   CANCER

Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence

(2018) Mara Gavazzoni et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A comparison of approaches to identify possible cases of local anesthetic systemic toxicity in the FDA Adverse Event Reporting System (FAERS) database

(2018) Simon Dagenais et al.   Expert Opinion On Drug Safety

Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis

(2018) Chintan Shah et al.   LEUKEMIA & LYMPHOMA

Carfilzomib-Associated Cardiovascular Adverse Events

(2018) Adam J. Waxman et al.   JAMA Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Propensity Score-Based Approaches in High Dimension for Pharmacovigilance Signal Detection: an Empirical Comparison on the French Spontaneous Reporting Database

(2018) Émeline Courtois et al.   Frontiers in Pharmacology

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

(2018) Joe-Elie Salem et al.   LANCET ONCOLOGY

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies

(2017) Andrzej J. Jakubowiak et al.   Hematology

Safety issues and management of toxicities associated with new treatments for multiple myeloma

(2017) Annamaria Brioli et al.   Expert Review of Hematology

Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies

(2017) Weijuan Li et al.   JAMA Oncology

Vascular Spasm: A Newly Unraveled Cause for Cardiovascular Adversity of Proteasome Inhibition

(2017) Xuejun Wang   EBioMedicine

Data mining spontaneous adverse drug event reports for safety signals in Singapore – a comparison of three different disproportionality measures

(2016) Pei San Ang et al.   Expert Opinion On Drug Safety

Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats

(2016) Faisal Imam et al.   TOXICOLOGY MECHANISMS AND METHODS

Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats

(2016) Faisal Imam et al.   TOXICOLOGY MECHANISMS AND METHODS

Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress

(2015) Faisal Imam et al.   Cardiovascular Toxicology

Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma

(2015) E. Wilson Grandin et al.   JOURNAL OF CARDIAC FAILURE

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring

(2014) Ajai Chari et al.   BMC CANCER

A comparison of disproportionality analysis methods in national adverse drug reaction databases of China

(2014) Yongfang Hou et al.   Expert Opinion On Drug Safety

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database

(2013) Elisabetta Poluzzi et al.   DRUG SAFETY

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

(2013) D. Siegel et al.   HAEMATOLOGICA

Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery

(2011) G Niklas Norén et al.   STATISTICAL METHODS IN MEDICAL RESEARCH